tt-00920
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 5, 2020 (NCT04364789)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Phosphodiesterase 9AINHIBITOR
PDE9A inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05355129 | Phase 1 | Nov 3, 2021 | TransThera Biosciences Co., Ltd |
| NCT05043792 | Phase 1 | Sep 20, 2021 | TransThera Biosciences Co., Ltd |
| NCT04364789 | Phase 1 | Feb 5, 2020 | Glendale Adventist Medical Center, TransThera Biosciences Co., Ltd |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| TransThera Biosciences Co., Ltd | For profit | 3 | 3 | 1 | 2020 |
| Glendale Adventist Medical Center | Academic/Hospital | 1 | 0 | 1 | 2020 |
2 organizations
Page 1 / 1